NEW YORK (GenomeWeb News) – SynapDx today announced a deal with Illumina aimed at the detection of autism spectrum disorders.

The deal will link SynapDx's autism technologies with Illumina's sequencing platforms to develop tools for the early detection of ASDs, SynapDx said, adding that the companies will also broadly evaluate other opportunities in neurodevelopment.

Further terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.